MENU CLOSE
About Us

Who We Are

Our Social Responsibility

Events

Exhibitions

Activeties

Members

Hospitals

Individuals

Companies

Member Benefits

 
Bio-medical projectsi

State Key Laboratory of Biotherapy

Cooperation

Achievement Exhibition

Scimea Journals

Signal Transduction and Targeted Therapy

News

News Information

 
Home   >  News
20 Aug 2019
608
Member Unit News | Vice Governor Wang Yihong Visits Brilliant Pharmaceutical for Research
scimea

Reproduced from Brilliant Pharmaceutical

3.jpg

On the morning of April 9, Vice Governor Wang Yihong of Sichuan Provincial People's Government, accompanied by Wu Qi, head of the Provincial Healthcare Security Administration, visited Chengdu Brilliant Pharmaceutical Group to investigate the group's participation in the pilot work of nationally centralized procurement of medicines and the related progress.

4.jpg

Vice Governor Wang Yihong and his team visited the Shuangliu production site of Chengdu Brilliant Pharmaceutical Group, and listened to its Chairman Su Zhonghai's report on the production, supply and quality assurance of the two "4+7" bid-winning drugs: Beixin and Baxin, as well as the construction progress of centralized production base for the state's small varieties of medicines (medicines under shortage). Besides, he learned in detail about the difficulties and challenges faced by the company, its production and operation status in recent years, and its development plan for the future.

5.jpg

Vice Governor Wang Yihong fully affirmed Brilliant Pharmaceutical's active participation in the state's pilot reform in centralized procurement of medicines, and its thoughtful arrangements in quality control, production, circulation and supply guarantee. He pointed out that the pilot project in centralized medicine procurement and use is a major strategic initiative made by the CPC Central Committee and the State Council, and is a critical reform of the current drug procurement model; enterprises shall change their mindsets, adapt to the needs of reform, and follow high standards and strict requirements to strengthen internal management, ensure the supply and quality of the selected drugs, to further establish corporate image; shall seize opportunities, increase input in research and development, stick to the development path of innovation, grow bigger and stronger, and safeguard people's health with quality medical services.


Liang Zong’an: Breathe Together and Share Future-Doctors in Action
Internal Training | Communication - Into the Hearts (II)
Breaking News | "Chinese Critical Care Analgesia and Sedation Summit 2019" Officially Opened
Internal Training | Learning from Success - Experience Sharing and Improvement of Professional Committee Work
MedComm | De novo lipogenesis is elicited dramatically in human hepatocellular carcinoma especially in hepatitis C virus‐induced hepatocellular carcinoma
Latest Events Journals News Members About Us Home
Contact Us

Address: No. 1103-1105, Building 6, S2, Global Center, High-tech Zone, Chengdu

Email: scimea@163.com 

Tel: (0086-)028-63859818   

Fax: (0086-)028-63859818   

Contact: (0086-)19113901604 (wechat:19113901604)


Follow Us
Copyright © 2009-2019 SCIMEA. All rights reserved 蜀ICP备19011649号-1